Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law FDA Moves to Reevaluate Several Peptides American Med Spa Association Sources: U.S. Food and Drug Administration (FDA) Compounding and the FDA (503A & 503B guidance) FDA warning letters on unapproved peptide products National Institutes of Health (NIH) PubMed Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance[v3] Preprints.org